Circulating biomarkers and cardiac function over 3  years after chemotherapy with anthracyclines: the ICOS‐ONE trial

ConclusionsFirst ‐in‐life CT with median cumulative dose of anthracyclines of 180 mg/m2 does not seem to cause clinically significant cardiac injury, as assessed by circulating biomarkers and echocardiography, in patients aged 51  years (median), without pre‐existing cardiac disease. This may suggest either a 100% efficacy of enalapril (given as preventive or troponin‐triggered) or a reassuringly low absolute cardiovascular risk in this cohort of patients, which may not require intensive cardiologic follow‐up.

Source: ESC Heart Failure - April 30, 2020 Category: Cardiology Authors: Jennifer M.T.A. Meessen, Daniela Cardinale, Fabio Ciceri, Maria Teresa Sandri, Maurizio Civelli, Barbara Bottazzi, GianFranco Cucchi, Elisabetta Menatti, Maurizio Mangiavacchi, Gianluigi Condorelli, Enrico Barbieri, Stefania Gori, Alessandro C Tags: Original Research Article Source Type: research